Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...
Company
Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...
RemeGen’s Executive Director He Ruyi Resigns for Career Development
China-based pharmaceutical firm RemeGen (HKG: 9995) announced the resignation of Mr. He Ruyi, Executive Director...
Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...
AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...
Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...
Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth
Germany-based Siemens Healthineers AG (ETR: SHL) released its results for the first quarter of fiscal...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...
Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s...
Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches
China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD...
Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products
Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...
CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA
China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...
Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...
Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease
China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval...
Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...
Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...
Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer
Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...
Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease
Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...
Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clinical trial approval from...